Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses

Advanced Drug Delivery Reviews

Volumn 79, Issue , 2014, Pages 193-213

  Loessner, Daniela ^a   Holzapfel, Boris Michael ^a,b   Clements, Judith Ann ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

3D culture models; Bone metastasis; Humanised; Intraperitoneal metastasis; Preclinical drug testing; Tissue engineering

Indexed keywords

BIOMIMETICS; BONE; CELL CULTURE; CELLS; DISEASES; PATHOLOGY; PHYSIOLOGICAL MODELS; TISSUE; TISSUE ENGINEERING; UROLOGY;

3-D CULTURES; BONE METASTASIS; DRUG TESTING; HUMANISED; INTRAPERITONEAL;

SCAFFOLDS (BIOLOGY);

ALGINIC ACID; BICALUTAMIDE; BIOMATERIAL; CASPASE 3; CASPASE 7; CATHEPSIN; COLLAGENASE; CYSTEINE PROTEINASE; ENZALUTAMIDE; GELATIN; GELATINASE A; GELATINASE B; HYALURONIC ACID; MACROGOL; MATRIX METALLOPROTEINASE; METHACRYLIC ACID; PACLITAXEL; PLATINUM; SERINE PROTEINASE; TAXANE DERIVATIVE; TRYPSIN; ANTINEOPLASTIC AGENT;

BIOENGINEERING; BONE; CANCER GROWTH; CANCER MODEL; CANCER RESISTANCE; CARCINOGENESIS; CELL CULTURE; COCULTURE; DRUG RESPONSE; HUMAN; HYDROGEL; METASTASIS; NONHUMAN; OVARY CANCER; PERITONEUM; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE STRUCTURE; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; BIOMIMETICS; CULTURE TECHNIQUE; DISEASE COURSE; FEMALE; MALE; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROSTATIC NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMIMETICS; CELL CULTURE TECHNIQUES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TISSUE ENGINEERING; TUMOR MICROENVIRONMENT;

EID: 84919660539     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.06.001     Document Type: Review

References (322)

1. Langer R., Vacanti J.P. Tissue engineering. Science 1993, 260:920-926.
2. Langer R., Tirrell D.A. Designing materials for biology and medicine. Nature 2004, 428:487-492.
3. Holzapfel B.M., Reichert J.C., Schantz J.T., Gbureck U., Rackwitz L., Noth U., Jakob F., Rudert M., Groll J., Hutmacher D.W. How smart do biomaterials need to be? A translational science and clinical point of view. Adv. Drug Deliv. Rev. 2013, 65:581-603.
4. Barcellos-Hoff M.H., Lyden D., Wang T.C. The evolution of the cancer niche during multistage carcinogenesis. Nat. Rev. Cancer 2013, 13:511-518.
5. Fidler I.J. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg. Oncol. Clin. N. Am. 2001, 10:257-269. (vii-viiii).
6. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
7. Holbeck S.L. Update on NCI in vitro drug screen utilities. Eur. J. Cancer 2004, 40:785-793.
8. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nat. Mater. 2010, 9:90-93.
9. Abbott A. Cell culture: biology's new dimension. Nature 2003, 424:870-872.
10. Krause S., Maffini M.V., Soto A.M., Sonnenschein C. The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer 2010, 10:263.
11. Olsen C.J., Moreira J., Lukanidin E.M., Ambartsumian N.S. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer 2010, 10:444.
12. Clark A.K., Taubenberger A.V., Taylor R.A., Niranjan B., Chea Z.Y., Zotenko E., Sieh S., Pedersen J.S., Norden S., Frydenberg M., Grummet J.P., Pook D.W., Stirzaker C., Clark S.J., Lawrence M.G., Ellem S.J., Hutmacher D.W., Risbridger G.P. A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials 2013, 34:4777-4785.
13. Hutmacher D.W., Loessner D., Rizzi S., Kaplan D.L., Mooney D.J., Clements J.A. Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol. 2010, 28:125-133.
14. Hutmacher D.W., Horch R.E., Loessner D., Rizzi S., Sieh S., Reichert J.C., Clements J.A., Beier J.P., Arkudas A., Bleiziffer O., Kneser U. Translating tissue engineering technology platforms into cancer research. J. Cell. Mol. Med. 2009, 13:1417-1427.
15. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31:8494-8506.
16. Loessner D., Rizzi S.C., Stok K.S., Fuehrmann T., Hollier B., Magdolen V., Hutmacher D.W., Clements J.A. A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread. Biomaterials 2013, 34:7389-7400.
17. Loessner D., Kobel S., Clements J.A., Lutolf M.P., Hutmacher D.W. Hydrogel microwell arrays allow the assessment of protease-associated enhancement of cancer cell aggregation and survival. Microarrays 2013, 2:208-227.
18. Kaemmerer E., Melchels F.P., Holzapfel B.M., Meckel T., Hutmacher D.W., Loessner D. Gelatine methacrylamide-based hydrogels: an alternative three-dimensional cancer cell culture system. Acta Biomater. 2014, 10:2551-2562.
19. Sieh S., Lubik A.A., Clements J.A., Nelson C.C., Hutmacher D.W. Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis 2010, 6:181-188.
20. Sieh S., Taubenberger A.V., Rizzi S.C., Sadowski M., Lehman M.L., Rockstroh A., An J., Clements J.A., Nelson C.C., Hutmacher D.W. Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment. PLoS One 2012, 7:e40217.
21. Holzapfel B.M., Thibaudeau L., Hesami P., Taubenberger A., Holzapfel N.P., Mayer-Wagner S., Power C., Clements J., Russell P., Hutmacher D.W. Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer Metastasis Rev. 2013, 32:129-145.
22. Sieh S., Taubenberger A.V., Lehman M.L., Clements J.A., Nelson C.C., Hutmacher D.W. Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone 2014, 63:121-131.
23. Hesami P., Holzapfel B.M., Taubenberger A., Roudier M., Fazli L., Sieh S., Thibaudeau L., Gregory L.S., Hutmacher D.W., Clements J.A. A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone. Clin. Exp. Metastasis 2014, 31(4):435-446.
24. Holzapfel B.M., Wagner F., Loessner D., Holzapfel N.P., Thibaudeau L., Crawford R., Ling M.T., Clements J.A., Russell P.J., Hutmacher D.W. Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials 2014, 35:4108-4115.
25. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
26. Sutcliffe S., Colditz G.A. Prostate cancer: is it time to expand the research focus to early-life exposures?. Nat. Rev. Cancer 2013, 13:208-518.
27. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9:167-181.
28. Risbridger G.P., Davis I.D., Birrell S.N., Tilley W.D. Breast and prostate cancer: more similar than different. Nat. Rev. Cancer 2010, 10:205-212.
29. Sethi N., Kang Y. Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat. Rev. Cancer 2011, 11:735-748.
30. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 2013, 13:714-726.
31. Vaughan S., Coward J.I., Bast R.C., Berchuck A., Berek J.S., Brenton J.D., Coukos G., Crum C.C., Drapkin R., Etemadmoghadam D., Friedlander M., Gabra H., Kaye S.B., Lord C.J., Lengyel E., Levine D.A., McNeish I.A., Menon U., Mills G.B., Nephew K.P., Oza A.M., Sood A.K., Stronach E.A., Walczak H., Bowtell D.D., Balkwill F.R. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11:719-725.
32. Karst A.M., Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J. Oncol. 2010, 2010:932371.
33. Auersperg N. The origin of ovarian cancers-hypotheses and controversies. Front. Biosci. 2013, 5:709-719.
34. Lengyel E. Ovarian cancer development and metastasis. Am. J. Pathol. 2010, 177:1053-1064.
35. Le Page C., Provencher D., Maugard C.M., Ouellet V., Mes-Masson A.M. Signature of a silent killer: expression profiling in epithelial ovarian cancer. Expert. Rev. Mol. Diagn. 2004, 4:157-167.
36. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 2009, 9:415-428.
37. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3:502-516.
38. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006, 354:34-43.
39. Lu Z., Wang J., Wientjes M.G., Au J.L. Intraperitoneal therapy for peritoneal cancer. Future Oncol. 2010, 6:1625-1641.
40. Sieh W., Kobel M., Longacre T.A., Bowtell D.D., deFazio A., Goodman M.T., Hogdall E., Deen S., Wentzensen N., Moysich K.B., Brenton J.D., Clarke B.A., Menon U., Gilks C.B., Kim A., Madore J., Fereday S., George J., Galletta L., Lurie G., Wilkens L.R., Carney M.E., Thompson P.J., Matsuno R.K., Kjaer S.K., Jensen A., Hogdall C., Kalli K.R., Fridley B.L., Keeney G.L., Vierkant R.A., Cunningham J.M., Brinton L.A., Yang H.P., Sherman M.E., Garcia-Closas M., Lissowska J., Odunsi K., Morrison C., Lele S., Bshara W., Sucheston L., Jimenez-Linan M., Driver K., Alsop J., Mack M., McGuire V., Rothstein J.H., Rosen B.P., Bernardini M.Q., Mackay H., Oza A., Wozniak E.L., Benjamin E., Gentry-Maharaj A., Gayther S.A., Tinker A.V., Prentice L.M., Chow C., Anglesio M.S., Johnatty S.E., Chenevix-Trench G., Whittemore A.S., Pharoah P.D., Goode E.L., Huntsman D.G., Ramus S.J. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013, 14:853-862.
41. Rosenthal S.A., Sandler H.M. Treatment strategies for high-risk locally advanced prostate cancer. Nat. Rev. Urol. 2010, 7:31-38.
42. Payne H. Management of locally advanced prostate cancer. Asian J. Androl. 2009, 11:81-87.
43. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 2002, 52:154-179.
44. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., Mihatsch M.J. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 2000, 31:578-583.
45. Galasko C.S. The anatomy and pathways of skeletal metastases. Bone Metastases 1981, 49-63. GK Hall, Boston. L. Weiss, A. Gilbert (Eds.).
46. Norgaard M., Jensen A.O., Jacobsen J.B., Cetin K., Fryzek J.P., Sorensen H.T. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J. Urol. 2010, 184:162-167.
47. Sturge J., Caley M.P., Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat. Rev. Clin. Oncol. 2011, 8:357-368.
48. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351:1502-1512.
49. Seruga B., Ocana A., Tannock I.F. Drug resistance in metastatic castration-resistant prostate cancer. Nat. Rev. Clin. Oncol. 2011, 8:12-23.
50. Karlou M., Tzelepi V., Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat. Rev. Urol. 2010, 7:494-509.
51. Kwon H., Kim H.J., Rice W.L., Subramanian B., Park S.H., Georgakoudi I., Kaplan D.L. Development of an in vitro model to study the impact of BMP-2 on metastasis to bone. J. Tissue Eng. Regen. Med. 2010, 4:590-599.
52. Yousef G.M., Diamandis E.P. The human kallikrein gene family: new biomarkers for ovarian cancer. Cancer Treat. Res. 2009, 149:165-187.
53. Yousef G.M., Polymeris M.E., Yacoub G.M., Scorilas A., Soosaipillai A., Popalis C., Fracchioli S., Katsaros D., Diamandis E.P. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 2003, 63:2223-2227.
54. Dorn J., Magdolen V., Gkazepis A., Gerte T., Harlozinska A., Sedlaczek P., Diamandis E.P., Schuster T., Harbeck N., Kiechle M., Schmitt M. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. Ann. Oncol. 2011, 22:1783-1790.
55. Schummer M., Drescher C., Forrest R., Gough S., Thorpe J., Hellstrom I., Hellstrom K.E., Urban N. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol. Oncol. 2012, 125:65-69.
56. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M., Drescher C., Urban N., Hellstrom K.E. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63:3695-3700.
57. Zheng Y., Katsaros D., Shan S.J., de la Longrais I.R., Porpiglia M., Scorilas A., Kim N.W., Wolfert R.L., Simon I., Li L., Feng Z., Diamandis E.P. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin. Cancer Res. 2007, 13:6984-6992.
58. Seiz L., Dorn J., Kotzsch M., Walch A., Grebenchtchikov N.I., Gkazepis A., Schmalfeldt B., Kiechle M., Bayani J., Diamandis E.P., Langer R., Sweep F.C., Schmitt M., Magdolen V. Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol. Chem. 2012, 393:391-401.
59. Dorn J., Gkazepis A., Kotzsch M., Kremer M., Propping C., Mayer K., Mengele K., Diamandis E.P., Kiechle M., Magdolen V., Schmitt M. Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. Biol. Chem. 2014, 395:95-107.
60. Diamandis E.P., Bast R.C., Gold P., Chu T.M., Magnani J.L. Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. Clin. Chem. 2013, 59:22-31.
61. Baron J.A. Screening for cancer with molecular markers: progress comes with potential problems. Nat. Rev. Cancer 2012, 12:368-371.
62. Bray F., Lortet-Tieulent J., Ferlay J., Forman D., Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur. J. Cancer 2010, 46:3040-3052.
63. Klotz L. Active surveillance for prostate cancer: overview and update. Curr. Treat. Options Oncol. 2013, 14:97-108.
64. Wilt T.J., MacDonald R., Hagerty K., Schellhammer P., Kramer B.S. Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst. Rev. 2008, CD007091.
65. Shapira I., Oswald M., Lovecchio J., Khalili H., Menzin A., Whyte J., Dos Santos L., Liang S., Bhuiya T., Keogh M., Mason C., Sultan K., Budman D., Gregersen P.K., Lee A.T. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br. J. Cancer 2014, 110:976-983.
66. Lin H.M., Castillo L., Mahon K.L., Chiam K., Lee B.Y., Nguyen Q., Boyer M.J., Stockler M.R., Pavlakis N., Marx G., Mallesara G., Gurney H., Clark S.J., Swarbrick A., Daly R.J., Horvath L.G. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br. J. Cancer 2014, 110:2462-2471.
67. Bell D.A., Scully R.E. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994, 73:1859-1864.
68. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 2004, 351:2519-2529.
69. Folkins A.K., Jarboe E.A., Roh M.H., Crum C.P. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol. Oncol. 2009, 113:391-396.
70. Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., Medeiros F., Callahan M.J., Garner E.O., Gordon R.W., Birch C., Berkowitz R.S., Muto M.G., Crum C.P. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007, 31:161-169.
71. Kim J., Coffey D.M., Creighton C.J., Yu Z., Hawkins S.M., Matzuk M.M. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3921-3926.
72. Karst A.M., Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat. Protoc. 2012, 7:1755-1764.
73. Perets R., Wyant G.A., Muto K.W., Bijron J.G., Poole B.B., Chin K.T., Chen J.Y., Ohman A.W., Stepule C.D., Kwak S., Karst A.M., Hirsch M.S., Setlur S.R., Crum C.P., Dinulescu D.M., Drapkin R. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013, 24:751-765.
74. Landen C.N., Birrer M.J., Sood A.K. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 2008, 26:995-1005.
75. Kurman R.J., Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 2010, 34:433-443.
76. Cho K.R., Shih Ie M. Ovarian cancer. Annu. Rev. Pathol. 2009, 4:287-313.
77. Soslow R.A. Histologic subtypes of ovarian carcinoma: an overview. Int. J. Gynecol. Pathol. 2008, 27:161-174.
78. Shih Ie M., Davidson B. Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol. 2009, 5:1641-1657.
79. Lech A., Daneva T., Pashova S., Gagov H., Crayton R., Kukwa W., Czarnecka A.M., Szczylik C. Ovarian cancer as a genetic disease. Front. Biosci. 2013, 18:543-563.
80. Yang J.Y., Yoshihara K., Tanaka K., Hatae M., Masuzaki H., Itamochi H., Takano M., Ushijima K., Tanyi J.L., Coukos G., Lu Y., Mills G.B., Verhaak R.G. Predicting time to ovarian carcinoma recurrence using protein markers. J. Clin. Invest. 2013, 123:3740-3750.
81. Lawrenson K., Gayther S.A. Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med. 2009, 6:e25.
82. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
83. Alsop K., Fereday S., Meldrum C., deFazio A., Emmanuel C., George J., Dobrovic A., Birrer M.J., Webb P.M., Stewart C., Friedlander M., Fox S., Bowtell D., Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 2012, 30:2654-2663.
84. Banerjee S., Kaye S.B. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin. Cancer Res. 2013, 19:961-968.
85. Gan A., Green A.R., Nolan C.C., Martin S., Deen S. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. Hum. Pathol. 2013, 44:1638-1647.
86. Latifi A., Luwor R.B., Bilandzic M., Nazaretian S., Stenvers K., Pyman J., Zhu H., Thompson E.W., Quinn M.A., Findlay J.K., Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 2012, 7:e46858.
87. Latifi A., Abubaker K., Castrechini N., Ward A.C., Liongue C., Dobill F., Kumar J., Thompson E.W., Quinn M.A., Findlay J.K., Ahmed N. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell. Biochem. 2011, 112:2850-2864.
88. De Marzo A.M., Meeker A.K., Zha S., Luo J., Nakayama M., Platz E.A., Isaacs W.B., Nelson W.G. Human prostate cancer precursors and pathobiology. Urology 2003, 62:55-62.
89. Bethel C.R., Chaudhary J., Anway M.D., Brown T.R. Gene expression changes are age-dependent and lobe-specific in the brown Norway rat model of prostatic hyperplasia. Prostate 2009, 69:838-850.
90. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24:1967-2000.
91. Grignon D.J. Unusual subtypes of prostate cancer. Mod. Pathol. 2004, 17:316-327.
92. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J.E., Wilson M., Socci N.D., Lash A.E., Heguy A., Eastham J.A., Scher H.I., Reuter V.E., Scardino P.T., Sander C., Sawyers C.L., Gerald W.L. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
93. Bethel C.R., Faith D., Li X., Guan B., Hicks J.L., Lan F., Jenkins R.B., Bieberich C.J., De Marzo A.M. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res. 2006, 66:10683-10690.
94. Voeller H.J., Augustus M., Madike V., Bova G.S., Carter K.C., Gelmann E.P. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 1997, 57:4455-4459.
95. Kim M.J., Bhatia-Gaur R., Banach-Petrosky W.A., Desai N., Wang Y., Hayward S.W., Cunha G.R., Cardiff R.D., Shen M.M., Abate-Shen C. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 2002, 62:2999-3004.
96. Gurel B., Iwata T., Koh C.M., Jenkins R.B., Lan F., Van Dang C., Hicks J.L., Morgan J., Cornish T.C., Sutcliffe S., Isaacs W.B., Luo J., De Marzo A.M. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 2008, 21:1156-1167.
97. Mosquera J.M., Perner S., Demichelis F., Kim R., Hofer M.D., Mertz K.D., Paris P.L., Simko J., Collins C., Bismar T.A., Chinnaiyan A.M., Rubin M.A. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J. Pathol. 2007, 212:91-101.
98. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
99. Mosquera J.M., Perner S., Genega E.M., Sanda M., Hofer M.D., Mertz K.D., Paris P.L., Simko J., Bismar T.A., Ayala G., Shah R.B., Loda M., Rubin M.A. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin. Cancer Res. 2008, 14:3380-3385.
100. Albadine R., Latour M., Toubaji A., Haffner M., Isaacs W.B., Meeker A.P.E.A.K., Demarzo A.M., Epstein J.I., Netto G.J. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod. Pathol. 2009, 22:1415-1422.
101. Gao H., Ouyang X., Banach-Petrosky W.A., Shen M.M., Abate-Shen C. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res. 2006, 66:7929-7933.
102. Sircar K., Yoshimoto M., Monzon F.A., Koumakpayi I.H., Katz R.L., Khanna A., Alvarez K., Chen G., Darnel A.D., Aprikian A.G., Saad F., Bismar T.A., Squire J.A. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol. 2009, 218:505-513.
103. Uzgare A.R., Isaacs J.T. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res. 2004, 64:6190-6199.
104. Ni J., Cozzi P., Hao J., Beretov J., Chang L., Duan W., Shigdar S., Delprado W., Graham P., Bucci J., Kearsley J., Li Y. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int. J. Biochem. Cell Biol. 2013, 45:2736-2748.
105. Jin J.K., Tien P.C., Cheng C.J., Song J.H., Huang C., Lin S.H., Gallick G.E. Talin1 phosphorylation activates beta1 integrins: a novel mechanism to promote prostate cancer bone metastasis. Oncogene 2014, [Epub ahead of print].
106. Li C.R., Su J.J., Wang W.Y., Lee M.T., Wang T.Y., Jiang K.Y., Li C.F., Hsu J.M., Chen C.K., Chen M., Jiang S.S., Weaver V.M., Tsai K.K. Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer. Am. J. Pathol. 2013, 182:363-374.
107. Hagberg Thulin M., Jennbacken K., Damber J.E., Welen K. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clin. Exp. Metastasis 2014, 31:269-283.
108. Lee J., Cuddihy M.J., Kotov N.A. Three-dimensional cell culture matrices: state of the art. Tissue Eng. Part B 2008, 14:61-86.
109. Ghajar C.M., Bissell M.J. Tumor engineering: the other face of tissue engineering. Tissue Eng. Part A 2010, 16:2153-2156.
110. Ingber D.E. Can cancer be reversed by engineering the tumor microenvironment?. Semin. Cancer Biol. 2008, 18:356-364.
111. Burdett E., Kasper F.K., Mikos A.G., Ludwig J.A. Engineering tumors: a tissue engineering perspective in cancer biology. Tissue Eng. Part B Rev. 2010, 16:351-359.
112. Even-Ram S., Yamada K.M. Cell migration in 3D matrix. Curr. Opin. Cell Biol. 2005, 17:524-532.
113. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
114. Serebriiskii I., Castello-Cros R., Lamb A., Golemis E.A., Cukierman E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol. 2008, 27:573-585.
115. Lescarbeau R.M., Seib F.P., Prewitz M., Werner C., Kaplan D.L. In vitro model of metastasis to bone marrow mediates prostate cancer castration resistant growth through paracrine and extracellular matrix factors. PLoS One 2012, 7:e40372.
116. Reichert J.C., Quent V.M., Burke L.J., Stansfield S.H., Clements J.A., Hutmacher D.W. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials 2010, 31:7928-7936.
117. Taubenberger A.V., Quent V.M., Thibaudeau L., Clements J.A., Hutmacher D.W. Delineating breast cancer cell interactions with engineered bone microenvironments. J. Bone Miner. Res. 2013, 28:1399-1411.
118. Hotary K.B., Allen E.D., Brooks P.C., Datta N.S., Long M.W., Weiss S.J. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003, 114:33-45.
119. Griffith L.G., Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 2006, 7:211-224.
120. Harma V., Virtanen J., Makela R., Happonen A., Mpindi J.P., Knuuttila M., Kohonen P., Lotjonen J., Kallioniemi O., Nees M. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010, 5:e10431.
121. Zaman M.H. The role of engineering approaches in analysing cancer invasion and metastasis. Nat. Rev. Cancer 2013, 13:596-603.
122. Xu F., Celli J., Rizvi I., Moon S., Hasan T., Demirci U. A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform. Biotechnol. J. 2011, 6:204-212.
123. Abramov Y., Carmi S., Cohen J.S., Anteby S.O., Ringel I. 31P-magnetic resonance spectra of ovarian cancer cells exposed to chemotherapy within a three-dimensional Matrigel construct. Oncol. Rep. 2012, 28:735-741.
124. Windus L.C., Kiss D.L., Glover T., Avery V.M. In vivo biomarker expression patterns are preserved in 3D cultures of prostate cancer. Exp. Cell Res. 2012, 318:2507-2519.
125. Windus L.C., Glover T.T., Avery V.M. Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer. Mol. Cancer 2013, 12:112.
126. Chu J.H., Yu S., Hayward S.W., Chan F.L. Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer. Prostate 2009, 69:428-442.
127. Jaeger A.A., Das C.K., Morgan N.Y., Pursley R.H., McQueen P.G., Hall M.D., Pohida T.J., Gottesman M.M. Microfabricated polymeric vessel mimetics for 3-D cancer cell culture. Biomaterials 2013, 34:8301-8313.
128. Brown R.A. In the beginning there were soft collagen-cell gels: towards better 3D connective tissue models?. Exp. Cell Res. 2013, 319:2460-2469.
129. Barbolina M.V., Adley B.P., Ariztia E.V., Liu Y., Stack M.S. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J. Biol. Chem. 2007, 282:4924-4931.
130. Moss N.M., Barbolina M.V., Liu Y., Sun L., Munshi H.G., Stack M.S. Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res. 2009, 69:7121-7129.
131. Harjanto D., Maffei J.S., Zaman M.H. Quantitative analysis of the effect of cancer invasiveness and collagen concentration on 3D matrix remodeling. PLoS One 2011, 6:e24891.
132. Pampaloni F., Reynaud E.G., Stelzer E.H. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 2007, 8:839-845.
133. Lutolf M.P., Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 2005, 23:47-55.
134. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., Mooney D.J. Engineering tumors with 3D scaffolds. Nat. Methods 2007, 4:855-860.
135. Lutolf M.P. Artificial ECM: expanding the cell biology toolbox in 3D. Integr. Biol. 2009, 1:235-241.
136. Bichsel C.A., Gobaa S., Kobel S., Secondini C., Thalmann G.N., Cecchini M.G., Lutolf M.P. Diagnostic microchip to assay 3D colony-growth potential of captured circulating tumor cells. Lab Chip 2012, 12:2313-2316.
137. Xu X., Gurski L.A., Zhang C., Harrington D.A., Farach-Carson M.C., Jia X. Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroids. Biomaterials 2012, 33:9049-9060.
138. Gurski L.A., Jha A.K., Zhang C., Jia X., Farach-Carson M.C. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 2009, 30:6076-6085.
139. David L., Dulong V., Le Cerf D., Chauzy C., Norris V., Delpech B., Lamacz M., Vannier J.P. Reticulated hyaluronan hydrogels: a model for examining cancer cell invasion in 3D. Matrix Biol. 2004, 23:183-193.
140. Burdick J.A., Prestwich G.D. Hyaluronic acid hydrogels for biomedical applications. Adv. Mater. 2011, 23:H41-H56.
141. Serban M.A., Scott A., Prestwich G.D. Use of hyaluronan-derived hydrogels for three-dimensional cell culture and tumor xenografts. Curr. Protoc. Cell Biol. 2008, 40:10.14.1-10.14.21.
142. Liu Y., Shu X.Z., Prestwich G.D. Tumor engineering: orthotopic cancer models in mice using cell-loaded, injectable, cross-linked hyaluronan-derived hydrogels. Tissue Eng. 2007, 13:1091-1101.
143. Gurski L.A., Xu X., Labrada L.N., Nguyen N.T., Xiao L., van Golen K.L., Jia X., Farach-Carson M.C. Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels. PLoS One 2012, 7:e50075.
144. Banzato A., Bobisse S., Rondina M., Renier D., Bettella F., Esposito G., Quintieri L., Melendez-Alafort L., Mazzi U., Zanovello P., Rosato A. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 2008, 14:3598-3606.
145. Fischbach C., Kong H.J., Hsiong S.X., Evangelista M.B., Yuen W., Mooney D.J. Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:399-404.
146. King S.M., Quartuccio S., Hilliard T.S., Inoue K., Burdette J.E. Alginate hydrogels for three-dimensional organ culture of ovaries and oviducts. J. Vis. Exp. 2011, 52:2804.
147. Levett P.A., Melchels F.P., Schrobback K., Hutmacher D.W., Malda J., Klein T.J. A biomimetic extracellular matrix for cartilage tissue engineering centered on photocurable gelatin, hyaluronic acid and chondroitin sulfate. Acta Biomater. 2014, 10:214-223.
148. Nichol J.W., Koshy S.T., Bae H., Hwang C.M., Yamanlar S., Khademhosseini A. Cell-laden microengineered gelatin methacrylate hydrogels. Biomaterials 2010, 31:5536-5544.
149. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
150. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:571-573.
151. Ribatti D., Mangialardi G., Vacca A. Stephen Paget and the 'seed and soil' theory of metastatic dissemination. Clin. Exp. Med. 2006, 6:145-149.
152. Mathot L., Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci. 2012, 103:626-631.
153. Bissell M. Q&A: Mina Bissell on tumors as organs. Cancer Discov. 2013, 3:7.
154. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
155. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
156. Bissell M.J., Kenny P.A., Radisky D.C. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:343-356.
157. Overall C.M., Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6:227-239.
158. Lengyel E., Burdette J.E., Kenny H.A., Matei D., Pilrose J., Haluska P., Nephew K.P., Hales D.B., Stack M.S. Epithelial ovarian cancer experimental models. Oncogene 2013, [Epub ahead of print].
159. Lawrence M.G., Taylor R.A., Toivanen R., Pedersen J., Norden S., Pook D.W., Frydenberg M., Papargiris M.M., Niranjan B., Richards M.G., Wang H., Collins A.T., Maitland N.J., Risbridger G.P. A preclinical xenograft model of prostate cancer using human tumors. Nat. Protoc. 2013, 8:836-848.
160. Freedman R.S., Deavers M., Liu J., Wang E. Peritoneal inflammation - a microenvironment for epithelial ovarian cancer (EOC). J. Transl. Med. 2004, 2:23.
161. Wang E., Ngalame Y., Panelli M.C., Nguyen-Jackson H., Deavers M., Mueller P., Hu W., Savary C.A., Kobayashi R., Freedman R.S., Marincola F.M. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin. Cancer Res. 2005, 11:113-122.
162. Drew A.F., Blick T.J., Lafleur M.A., Tim E.L., Robbie M.J., Rice G.E., Quinn M.A., Thompson E.W. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice. Gynecol. Oncol. 2004, 95:437-448.
163. Bhowmick N.A., Moses H.L. Tumor-stroma interactions. Curr. Opin. Genet. Dev. 2005, 15:97-101.
164. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
165. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
166. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
167. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
168. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
169. Leinster D.A., Kulbe H., Everitt G., Thompson R., Perretti M., Gavins F.N., Cooper D., Gould D., Ennis D.P., Lockley M., McNeish I.A., Nourshargh S., Balkwill F.R. The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J. Pathol. 2012, 227:136-145.
170. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D.A., Thompson R., Schioppa T., Nemeth J., Vermeulen J., Singh N., Avril N., Cummings J., Rexhepaj E., Jirstrom K., Gallagher W.M., Brennan D.J., McNeish I.A., Balkwill F.R. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 2011, 17:6083-6096.
171. Kulbe H., Chakravarty P., Leinster D.A., Charles K.A., Kwong J., Thompson R.G., Coward J.I., Schioppa T., Robinson S.C., Gallagher W.M., Galletta L., Salako M.A., Smyth J.F., Hagemann T., Brennan D.J., Bowtell D.D., Balkwill F.R. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012, 72:66-75.
172. Coward J.I., Kulbe H. The role of interleukin-6 in gynaecological malignancies. Cytokine Growth Factor Rev. 2012, 23:333-342.
173. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315:1650-1659.
174. Ness R.B., Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl. Cancer Inst. 1999, 91:1459-1467.
175. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
176. Brown T.D., Slotosch A., Thibaudeau L., Taubenberger A., Loessner D., Vaquette C., Dalton P.D., Hutmacher D.W. Design and fabrication of tubular scaffolds via direct writing in a melt electrospinning mode. Biointerphases 2012, 7:13.
177. Iwanicki M.P., Davidowitz R.A., Ng M.R., Besser A., Muranen T., Merritt M., Danuser G., Ince T.A., Brugge J.S. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011, 1:144-157.
178. Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., Romero I.L., Carey M.S., Mills G.B., Hotamisligil G.S., Yamada S.D., Peter M.E., Gwin K., Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 2011, 17:1498-1503.
179. Kenny H.A., Kaur S., Coussens L.M., Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Invest. 2008, 118:1367-1379.
180. Kenny H.A., Krausz T., Yamada S.D., Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int. J. Cancer 2007, 121:1463-1472.
181. Touboul C., Lis R., Al Farsi H., Raynaud C.M., Warfa M., Althawadi H., Mery E., Mirshahi M., Rafii A. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J. Transl. Med. 2013, 11:28.
182. Wang R., Xu J., Juliette L., Castilleja A., Love J., Sung S.Y., Zhau H.E., Goodwin T.J., Chung L.W. Three-dimensional co-culture models to study prostate cancer growth, progression, and metastasis to bone. Semin. Cancer Biol. 2005, 15:353-364.
183. Kovacic N., Croucher P.I., McDonald M.M. Signaling between tumor cells and the host bone marrow microenvironment. Calcif. Tissue Int. 2014, 94:125-139.
184. Chu G.C., Zhau H.E., Wang R., Rogatko A., Feng X., Zayzafoon M., Liu Y., Farach-Carson M.C., You S., Kim J., Freeman M.R., Chung L.W. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr. Relat. Cancer 2014, 21:311-326.
185. Krausz E., de Hoogt R., Gustin E., Cornelissen F., Grand-Perret T., Janssen L., Vloemans N., Wuyts D., Frans S., Axel A., Peeters P.J., Hall B., Cik M. Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening. J. Biomol. Screen. 2013, 18:54-66.
186. Curtin P., Youm H., Salih E. Three-dimensional cancer-bone metastasis model using ex-vivo co-cultures of live calvarial bones and cancer cells. Biomaterials 2012, 33:1065-1078.
187. Fang X., Sittadjody S., Gyabaah K., Opara E.C., Balaji K.C. Novel 3D co-culture model for epithelial-stromal cells interaction in prostate cancer. PLoS One 2013, 8:e75187.
188. Varzavand A., Drake J.M., Svensson R.U., Herndon M.E., Zhou B., Henry M.D., Stipp C.S. Integrin alpha3beta1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization. Clin. Exp. Metastasis 2013, 30:541-552.
189. Seano G., Chiaverina G., Gagliardi P.A., di Blasio L., Sessa R., Bussolino F., Primo L. Modeling human tumor angiogenesis in a three-dimensional culture system. Blood 2013, 121:e129-e137.
190. Florczyk S.J., Liu G., Kievit F.M., Lewis A.M., Wu J.D., Zhang M. 3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro. Adv. Health Mater. 2012, 1:590-599.
191. Batra J., O'Mara T., Patnala R., Lose F., Clements J.A. Genetic polymorphisms in the human tissue kallikrein (KLK) locus and their implication in various malignant and non-malignant diseases. Biol. Chem. 2012, 393:1365-1390.
192. Ryan B.M., Robles A.I., Harris C.C. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 2010, 10:389-402.
193. Lawrence M.G., Lai J., Clements J.A. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr. Rev. 2010, 31:407-446.
194. Batra J., Nagle C.M., O'Mara T., Higgins M., Dong Y., Tan O.L., Lose F., Skeie L.M., Srinivasan S., Bolton K.L., Song H., Ramus S.J., Gayther S.A., Pharoah P.D., Kedda M.A., Spurdle A.B., Clements J.A. A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. BMC Cancer 2011, 11:119.
195. O'Mara T.A., Nagle C.M., Batra J., Kedda M.A., Clements J.A., Spurdle A.B. Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival. Twin Res. Hum. Genet. 2011, 14:323-327.
196. Batra J., Lose F., O'Mara T., Marquart L., Stephens C., Alexander K., Srinivasan S., Eeles R.A., Easton D.F., Al Olama A.A., Kote-Jarai Z., Guy M., Muir K., Lophatananon A., Rahman A.A., Neal D.E., Hamdy F.C., Donovan J.L., Chambers S., Gardiner R.A., Aitken J., Yaxley J., Kedda M.A., Clements J.A., Spurdle A.B. Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. PLoS One 2011, 6:e26527.
197. Lose F., Srinivasan S., O'Mara T., Marquart L., Chambers S., Gardiner R.A., Aitken J.F., Spurdle A.B., Batra J., Clements J.A. Genetic association of the KLK4 locus with risk of prostate cancer. PLoS One 2012, 7:e44520.
198. Lose F., Lawrence M.G., Srinivasan S., O'Mara T., Marquart L., Chambers S., Gardiner R.A., Aitken J.F., Spurdle A.B., Batra J., Clements J.A. The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness. Biol. Chem. 2012, 393:403-412.
199. Chow T.F., Crow M., Earle T., El-Said H., Diamandis E.P., Yousef G.M. Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol. Chem. 2008, 389:731-738.
200. Di Leva G., Croce C.M. The role of microRNAs in the tumorigenesis of ovarian cancer. Front. Oncol. 2013, 3:153.
201. Neijenhuis S., Bajrami I., Miller R., Lord C.J., Ashworth A. Identification of miRNA modulators to PARP inhibitor response. DNA Repair 2013, 12:394-402.
202. Corney D.C., Nikitin A.Y. MicroRNA and ovarian cancer. Histol. Histopathol. 2008, 23:1161-1169.
203. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., Taccioli C., Volinia S., Liu C.G., Alder H., Calin G.A., Menard S., Croce C.M. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67:8699-8707.
204. White N.M., Chow T.F., Mejia-Guerrero S., Diamandis M., Rofael Y., Faragalla H., Mankaruous M., Gabril M., Girgis A., Yousef G.M. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br. J. Cancer 2010, 102:1244-1253.
205. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67:6130-6135.
206. Shi X.B., Xue L., Yang J., Ma A.H., Zhao J., Xu M., Tepper C.G., Evans C.P., Kung H.J., deVere White R.W. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19983-19988.
207. White N.M., Youssef Y.M., Fendler A., Stephan C., Jung K., Yousef G.M. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biol. Chem. 2012, 393:379-389.
208. Sotiropoulou G., Pampalakis G., Lianidou E., Mourelatos Z. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 2009, 15:1443-1461.
209. Chou J., Werb Z. MicroRNAs play a big role in regulating ovarian cancer-associated fibroblasts and the tumor microenvironment. Cancer Discov. 2012, 2:1078-1080.
210. Mitra A.K., Zillhardt M., Hua Y., Tiwari P., Murmann A.E., Peter M.E., Lengyel E. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012, 2:1100-1108.
211. Nishimura M., Jung E.J., Shah M.Y., Lu C., Spizzo R., Shimizu M., Han H.D., Ivan C., Rossi S., Zhang X., Nicoloso M.S., Wu S.Y., Almeida M.I., Bottsford-Miller J., Pecot C.V., Zand B., Matsuo K., Shahzad M.M., Jennings N.B., Rodriguez-Aguayo C., Lopez-Berestein G., Sood A.K., Calin G.A. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013, 3:1302-1315.
212. Schmalfeldt B., Prechtel D., Harting K., Spathe K., Rutke S., Konik E., Fridman R., Berger U., Schmitt M., Kuhn W., Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 2001, 7:2396-2404.
213. Riddick A.C., Shukla C.J., Pennington C.J., Bass R., Nuttall R.K., Hogan A., Sethia K.K., Ellis V., Collins A.T., Maitland N.J., Ball R.Y., Edwards D.R. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer 2005, 92:2171-2180.
214. Lopez-Otin C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7:800-808.
215. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
216. Kajiyama H., Kikkawa F., Khin E., Shibata K., Ino K., Mizutani S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res. 2003, 63:2278-2283.
217. Wesley U.V., McGroarty M., Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 2005, 65:1325-1334.
218. Horiguchi A., Zheng R., Goodman O.B., Shen R., Guan H., Hersh L.B., Nanus D.M. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth. Cancer Gene Ther. 2007, 14:583-589.
219. Ghosh A., Wang X., Klein E., Heston W.D. Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res. 2005, 65:727-731.
220. Fuhrman-Luck R.A., Silva M.L., Dong Y., Irving-Rodgers H., Stoll T., Hastie M.L., Loessner D., Gorman J.J., Clements J.A. Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer. Proteomics Clin. Appl. 2014, 8(5-6):403-415.
221. Lee S.H., Miller J.S., Moon J.J., West J.L. Proteolytically degradable hydrogels with a fluorogenic substrate for studies of cellular proteolytic activity and migration. Biotechnol. Prog. 2005, 21:1736-1741.
222. Niggemann B., Drell T.L.t., Joseph J., Weidt C., Lang K., Zaenker K.S., Entschladen F. Tumor cell locomotion: differential dynamics of spontaneous and induced migration in a 3D collagen matrix. Exp. Cell Res. 2004, 298:178-187.
223. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I., Strongin A.Y., Brocker E.B., Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003, 160:267-277.
224. Sahai E., Marshall C.J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol. 2003, 5:711-719.
225. Ehrbar M., Sala A., Lienemann P., Ranga A., Mosiewicz K., Bittermann A., Rizzi S.C., Weber F.E., Lutolf M.P. Elucidating the role of matrix stiffness in 3D cell migration and remodeling. Biophys. J. 2011, 100:284-293.
226. Mason S.D., Joyce J.A. Proteolytic networks in cancer. Trends Cell Biol. 2011, 21:228-237.
227. Packard B.Z., Artym V.V., Komoriya A., Yamada K.M. Direct visualization of protease activity on cells migrating in three-dimensions. Matrix Biol. 2009, 28:3-10.
228. Gill J.H., Loadman P.M., Shnyder S.D., Cooper P., Atkinson J.M., Ribeiro Morais G., Patterson L.H., Falconer R.A. Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity. Mol. Pharm. 2014, 11(4):1294-1300.
229. Lu P., Takai K., Weaver V.M., Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 2011, 3. (pii: a005058).
230. Podgorski I., Linebaugh B.E., Sameni M., Jedeszko C., Bhagat S., Cher M.L., Sloane B.F. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia 2005, 7:207-223.
231. Sameni M., Cavallo-Medved D., Dosescu J., Jedeszko C., Moin K., Mullins S.R., Olive M.B., Rudy D., Sloane B.F. Imaging and quantifying the dynamics of tumor-associated proteolysis. Clin. Exp. Metastasis 2009, 26:299-309.
232. Sameni M., Anbalagan A., Olive M.B., Moin K., Mattingly R.R., Sloane B.F. MAME models for 4D live-cell imaging of tumor: microenvironment interactions that impact malignant progression. J. Vis. Exp. 2012, 60. (pii: 3661).
233. Lutolf M.P., Lauer-Fields J.L., Schmoekel H.G., Metters A.T., Weber F.E., Fields G.B., Hubbell J.A. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5413-5418.
234. Lee S.H., Moon J.J., Miller J.S., West J.L. Poly(ethylene glycol) hydrogels conjugated with a collagenase-sensitive fluorogenic substrate to visualize collagenase activity during three-dimensional cell migration. Biomaterials 2007, 28:3163-3170.
235. DeForest C.A., Polizzotti B.D., Anseth K.S. Sequential click reactions for synthesizing and patterning three-dimensional cell microenvironments. Nat. Mater. 2009, 8:659-664.
236. Leight J.L., Alge D.L., Maier A.J., Anseth K.S. Direct measurement of matrix metalloproteinase activity in 3D cellular microenvironments using a fluorogenic peptide substrate. Biomaterials 2013, 34:7344-7352.
237. Horino K., Kindezelskii A.L., Elner V.M., Hughes B.A., Petty H.R. Tumor cell invasion of model 3-dimensional matrices: demonstration of migratory pathways, collagen disruption, and intercellular cooperation. FASEB J. 2001, 15:932-939.
238. Wolf K., Friedl P. Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin. Exp. Metastasis 2009, 26:289-298.
239. Weissleder R. Molecular imaging in cancer. Science 2006, 312:1168-1171.
240. Hensley H.H., Roder N.A., O'Brien S.W., Bickel L.E., Xiao F., Litwin S., Connolly D.C. Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice. Neoplasia 2012, 14:451-462.
241. Deu E., Verdoes M., Bogyo M. New approaches for dissecting protease functions to improve probe development and drug discovery. Nat. Struct. Mol. Biol. 2012, 19:9-16.
242. Verdoes M., Oresic Bender K., Segal E., van der Linden W.A., Syed S., Withana N.P., Sanman L.E., Bogyo M. An improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J. Am. Chem. Soc. 2013, 135:14726-14730.
243. Mullins S.R., Sameni M., Blum G., Bogyo M., Sloane B., Moin K. Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biol. Chem. 2012, 393:1405-1416.
244. Barry Z.T., Platt M.O. Cathepsin S cannibalism of cathepsin K as a mechanism to reduce type I collagen degradation. J. Biol. Chem. 2012, 287:27723-27730.
245. Godinat A., Park H.M., Miller S.C., Cheng K., Hanahan D., Sanman L.E., Bogyo M., Yu A., Nikitin G.F., Stahl A., Dubikovskaya E.A. A biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice. ACS Chem. Biol. 2013, 8:987-999.
246. Swedberg J.E., Nigon L.V., Reid J.C., de Veer S.J., Walpole C.M., Stephens C.R., Walsh T.P., Takayama T.K., Hooper J.D., Clements J.A., Buckle A.M., Harris J.M. Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4. Chem. Biol. 2009, 16:633-643.
247. Dong Y., Stephens C., Walpole C., Swedberg J.E., Boyle G.M., Parsons P.G., McGuckin M.A., Harris J.M., Clements J.A. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One 2013, 8:e57056.
248. Gillet J.P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:18708-18713.
249. Domcke S., Sinha R., Levine D.A., Sander C., Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 2013, 4:2126.
250. Kunz-Schughart L.A., Freyer J.P., Hofstaedter F., Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J. Biomol. Screen. 2004, 9:273-285.
251. Pampaloni F., Stelzer E.H., Masotti A. Three-dimensional tissue models for drug discovery and toxicology. Recent Pat. Biotechnol. 2009, 3:103-117.
252. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
253. Myungjin Lee J., Mhawech-Fauceglia P., Lee N., Cristina Parsanian L., Gail Lin Y., Andrew Gayther S., Lawrenson K. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab. Invest. 2013, 93:528-542.
254. Lee M.Y., Kumar R.A., Sukumaran S.M., Hogg M.G., Clark D.S., Dordick J.S. Three-dimensional cellular microarray for high-throughput toxicology assays. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:59-63.
255. Evensen N.A., Li J., Yang J., Yu X., Sampson N.S., Zucker S., Cao J. Development of a high-throughput three-dimensional invasion assay for anti-cancer drug discovery. PLoS One 2013, 8:e82811.
256. Hensley H., Quinn B.A., Wolf R.L., Litwin S.L., Mabuchi S., Williams S.J., Williams C., Hamilton T.C., Connolly D.C. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol. Ther. 2007, 6:1717-1725.
257. Jones P.M., Drapkin R. Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms. Front. Oncol. 2013, 3:217.
258. Rosol T.J., Tannehill-Gregg S.H., LeRoy B.E., Mandl S., Contag C.H. Animal models of bone metastasis. Cancer 2003, 97:748-757.
259. Connolly D.C., Hensley H.H. Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents. Curr. Protoc. Pharmacol. 2009, 45:14.12.1-14.12.26.
260. Scott C.L., Becker M.A., Haluska P., Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front. Oncol. 2013, 3:295.
261. Rangarajan A., Weinberg R.A. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer 2003, 3:952-959.
262. Holzapfel B.M., Chhaya M.P., Melchels F.P., Holzapfel N.P., Prodinger P.M., von Eisenhart-Rothe R., van Griensven M., Schantz J.T., Rudert M., Hutmacher D.W. Can bone tissue engineering contribute to therapy concepts after resection of musculoskeletal sarcoma?. Sarcoma 2013, 2013:153640.
263. Johnson P.A., Giles J.R. The hen as a model of ovarian cancer. Nat. Rev. Cancer 2013, 13:432-436.
264. Tseng C.L., Peng C.L., Huang J.Y., Chen J.C., Lin F.H. Gelatin nanoparticles as gene carriers for transgenic chicken applications. J. Biomater. Appl. 2013, 27:1055-1065.
265. Naora H., Montell D.J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev. Cancer 2005, 5:355-366.
266. Shaw T.J., Senterman M.K., Dawson K., Crane C.A., Vanderhyden B.C. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 2004, 10:1032-1042.
267. Cho K.R. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch. Pathol. Lab. Med. 2009, 133:1775-1781.
268. Orsulic S., Li Y., Soslow R.A., Vitale-Cross L.A., Gutkind J.S., Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002, 1:53-62.
269. Howell V.M. Genetically engineered mouse models for epithelial ovarian cancer: are we there yet?. Semin. Cell Dev. Biol. 2014, 27C:106-117.
270. Katz E., Skorecki K., Tzukerman M. Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations. Clin. Cancer Res. 2009, 15:70-80.
271. Corey E., Quinn J.E., Bladou F., Brown L.G., Roudier M.P., Brown J.M., Buhler K.R., Vessella R.L. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002, 52:20-33.
272. Fizazi K., Yang J., Peleg S., Sikes C.R., Kreimann E.L., Daliani D., Olive M., Raymond K.A., Janus T.J., Logothetis C.J., Karsenty G., Navone N.M. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin. Cancer Res. 2003, 9:2587-2597.
273. Yonou H., Kanomata N., Goya M., Kamijo T., Yokose T., Hasebe T., Nagai K., Hatano T., Ogawa Y., Ochiai A. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 2003, 63:2096-2102.
274. Yonou H., Ochiai A., Goya M., Kanomata N., Hokama S., Morozumi M., Sugaya K., Hatano T., Ogawa Y. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 2004, 58:406-413.
275. Yonou H., Yokose T., Kamijo T., Kanomata N., Hasebe T., Nagai K., Hatano T., Ogawa Y., Ochiai A. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res. 2001, 61:2177-2182.
276. Banerjee S., Hussain M., Wang Z., Saliganan A., Che M., Bonfil D., Cher M., Sarkar F.H. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007, 67:3818-3826.
277. Deng X., He G., Levine A., Cao Y., Mullins C. Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. Int. J. Cancer 2008, 122:209-218.
278. Nemeth J.A., Harb J.F., Barroso U., He Z., Grignon D.J., Cher M.L. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res. 1999, 59:1987-1993.
279. Hubin F., Humblet C., Belaid Z., Greimers R., Boniver J., Thiry A., Defresne M.P. Maintenance of functional human cancellous bone and human hematopoiesis in NOD/SCID mice. Cell Transplant. 2004, 13:823-831.
280. Kuperwasser C., Dessain S., Bierbaum B.E., Garnet D., Sperandio K., Gauvin G.P., Naber S.P., Weinberg R.A., Rosenblatt M. A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005, 65:6130-6138.
281. Murphy W.J., Kumar V., Bennett M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J. Exp. Med. 1987, 165:1212-1217.
282. Kaplan R.N., Rafii S., Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 2006, 66:11089-11093.
283. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
284. Shiozawa Y., Pedersen E.A., Havens A.M., Jung Y., Mishra A., Joseph J., Kim J.K., Patel L.R., Ying C., Ziegler A.M., Pienta M.J., Song J., Wang J., Loberg R.D., Krebsbach P.H., Pienta K.J., Taichman R.S. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 2011, 121:1298-1312.
285. Wang C., Shen Y. Study on the distribution features of bone metastases in prostate cancer. Nucl. Med. Commun. 2012, 33:379-383.
286. Bakondi B., Spees J.L. Human CD133-derived bone marrow stromal cells establish ectopic hematopoietic microenvironments in immunodeficient mice. Biochem. Biophys. Res. Commun. 2010, 400:212-218.
287. Haynesworth S.E., Goshima J., Goldberg V.M., Caplan A.I. Characterization of cells with osteogenic potential from human marrow. Bone 1992, 13:81-88.
288. Krebsbach P.H., Kuznetsov S.A., Satomura K., Emmons R.V., Rowe D.W., Robey P.G. Bone formation in vivo: comparison of osteogenesis by transplanted mouse and human marrow stromal fibroblasts. Transplantation 1997, 63:1059-1069.
289. Kuznetsov S.A., Krebsbach P.H., Satomura K., Kerr J., Riminucci M., Benayahu D., Robey P.G. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J. Bone Miner. Res. 1997, 12:1335-1347.
290. Miura Y., Gao Z., Miura M., Seo B.M., Sonoyama W., Chen W., Gronthos S., Zhang L., Shi S. Mesenchymal stem cell-organized bone marrow elements: an alternative hematopoietic progenitor resource. Stem Cells 2006, 24:2428-2436.
291. Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S., Saggio I., Tagliafico E., Ferrari S., Robey P.G., Riminucci M., Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131:324-336.
292. Vaiselbuh S.R., Edelman M., Lipton J.M., Liu J.M. Ectopic human mesenchymal stem cell-coated scaffolds in NOD/SCID mice: an in vivo model of the leukemia niche. Tissue Eng. Part C Methods 2010, 16:1523-1531.
293. Scotti C., Piccinini E., Takizawa H., Todorov A., Bourgine P., Papadimitropoulos A., Barbero A., Manz M.G., Martin I. Engineering of a functional bone organ through endochondral ossification. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3997-4002.
294. Schneider A., Taboas J.M., McCauley L.K., Krebsbach P.H. Skeletal homeostasis in tissue-engineered bone. J. Orthop. Res. 2003, 21:859-864.
295. Song J., Kiel M.J., Wang Z., Wang J., Taichman R.S., Morrison S.J., Krebsbach P.H. An in vivo model to study and manipulate the hematopoietic stem cell niche. Blood 2010, 115:2592-2600.
296. Paraguassu-Braga F.H., Alves A.P., Santos I.M., Bonamino M., Bonomo A. An ectopic stromal implant model for hematopoietic reconstitution and in vivo evaluation of bone marrow niches. Cell Transplant. 2012, 21:2677-2688.
297. Reddi A.H., Anderson W.A. Collagenous bone matrix-induced endochondral ossification hemopoiesis. J. Cell Biol. 1976, 69:557-572.
298. Chen Y., Jacamo R., Shi Y.X., Wang R.Y., Battula V.L., Konoplev S., Strunk D., Hofmann N.A., Reinisch A., Konopleva M., Andreeff M. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood 2012, 119:4971-4980.
299. Schuster J., Zhang J., Longo M. A novel human osteoblast-derived severe combined immunodeficiency mouse model of bone metastasis. J. Neurosurg. Spine 2006, 4:388-391.
300. Moreau J.E., Anderson K., Mauney J.R., Nguyen T., Kaplan D.L., Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res. 2007, 67:10304-10308.
301. Goldstein R.H., Reagan M.R., Anderson K., Kaplan D.L., Rosenblatt M. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res. 2010, 70:10044-10050.
302. Moreau J., Anderson K.M., Mauney J.R., Kaplan D., Rosenblatt M. Studies of osteotropism on both sides of the breast cancer-bone interaction. Ann. N. Y. Acad. Sci. 2007, 1117:328-344.
303. Wan L., Pantel K., Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat. Med. 2013, 19:1450-1464.
304. Suresh S. Biomechanics and biophysics of cancer cells. Acta Biomater. 2007, 3:413-438.
305. Kumar S., Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009, 28:113-127.
306. Xu W., Mezencev R., Kim B., Wang L., McDonald J., Sulchek T. Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. PLoS One 2012, 7:e46609.
307. Swaminathan V., Mythreye K., O'Brien E.T., Berchuck A., Blobe G.C., Superfine R. Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res. 2011, 71:5075-5080.
308. Binnig G., Quate C.F., Gerber C. Atomic force microscope. Phys. Rev. Lett. 1986, 56:930-933.
309. Cross S.E., Jin Y.S., Rao J., Gimzewski J.K. Nanomechanical analysis of cells from cancer patients. Nat. Nanotechnol. 2007, 2:780-783.
310. Sharma S., Santiskulvong C., Bentolila L.A., Rao J.Y., Dorigo O., Gimzewski J.K. Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. Nanomedicine 2012, 8:757-766.
311. Loessner D., Little J.P., Pettet G.J., Hutmacher D.W. A multiscale road map of cancer spheroids - incorporating experimental and mathematical modelling to understand cancer progression. J. Cell Sci. 2013, 126:2761-2771.
312. Deisboeck T.S., Wang Z., Macklin P., Cristini V. Multiscale cancer modeling. Annu. Rev. Biomed. Eng. 2011, 13:127-155.
313. Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat. Rev. Cancer 2009, 9:108-122.
314. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., Reinhart-King C.A., Margulies S.S., Dembo M., Boettiger D., Hammer D.A., Weaver V.M. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
315. Qazi H., Palomino R., Shi Z.D., Munn L.L., Tarbell J.M. Cancer cell glycocalyx mediates mechanotransduction and flow-regulated invasion. Integr. Biol. 2013, 5:1334-1343.
316. Harjanto D., Zaman M.H. Computational study of proteolysis-driven single cell migration in a three-dimensional matrix. Ann. Biomed. Eng. 2010, 38:1815-1825.
317. Araujo A., Cook L.M., Lynch C.C., Basanta D. An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. Cancer Res. 2014, 74:2391-2401.
318. Harjanto D., Zaman M.H. Modeling extracellular matrix reorganization in 3D environments. PLoS One 2013, 8:e52509.
319. Huveneers S., Danen E.H. Adhesion signaling - crosstalk between integrins, Src and Rho. J. Cell Sci. 2009, 122:1059-1069.
320. Bainer R., Weaver V. Cell biology. Strength under tension. Science 2013, 341:965-966.
321. Swift J., Ivanovska I.L., Buxboim A., Harada T., Dingal P.C., Pinter J., Pajerowski J.D., Spinler K.R., Shin J.W., Tewari M., Rehfeldt F., Speicher D.W., Discher D.E. Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. Science 2013, 341:1240104.
322. Schwartz M.A., Chen C.S. Cell biology. Deconstructing dimensionality. Science 2013, 339:402-404.